Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 128

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 128
---
 agreement with respect to countries other than those for which the patents
were licensed to develop, use, offer for sale, sell, and otherwise commercialize in any manner whatsoever clinical products.

Radiopharm paid US$10 million
as an upfront fee, partly in cash and in shares. Radiopharm shall pay TRIMT up to US$90 million upon achievement of the several development
milestones and single-digit royalty rates on net sales of products covered by the licensed patents.

The agreement will
expire, on a country-by-country and product-by-product developed under the agreement basis, at the later of (i) the fifth year after
the last to expire patent right; or (ii) five years after expiring of any exclusivity (e. g. data/market exclusivity), or price, or
reimbursement protection (e. g. orphan drug exclusivity in the United States); or (iii) ten years after the first commercial sale of
a licensed product in the respective country. The expected expiry date of the last-to-expire patent is 2041. The agreement may also
be terminated if the head license between TRIMT and Bayerische Patentallianz GmbH is terminated, and by either party for cause. In
addition, Radiopharm may terminate the agreement at will upon delivering written notice.

License Agreement with Diaprost and Fredax

In September 2021, Radiopharm
entered into a license agreement with Diaprost AB (“ Diaprost”) and Fredax AB (“ Fredax”), a company related to
Diaprost, for the development of antibodies used in diagnostics, prognostics and therapeutics for prostate cancer. Under this agreement,
Fredax granted Radiopharm an exclusive, worldwide, sublicensable license of patent rights regarding antibody polypeptides and their uses.
Diaprost granted Radiopharm an exclusive worldwide sublicensable sublicense of patent rights regarding antibody polypeptides and their
uses.

Radiopharm has paid US$7 million
in upfront fees. In addition, under the agreement, Radiopharm will pay Diaprost an aggregate amount equal to US$122 million upon achievement
of several therapeutic clinical development and regulatory approval milestones as well as royalties upon entering into any sub-licensing
agreement that are based upon industry standard royalty rates. For further details, please see Note 13(b) to our fiscal 2025 audited financial
statements in this Annual Report.

The agreement will be effective
until the later